CN101176708A - Carmofur sustained-release implantation agent for curing entity tumour - Google Patents

Carmofur sustained-release implantation agent for curing entity tumour Download PDF

Info

Publication number
CN101176708A
CN101176708A CNA2007102028868A CN200710202886A CN101176708A CN 101176708 A CN101176708 A CN 101176708A CN A2007102028868 A CNA2007102028868 A CN A2007102028868A CN 200710202886 A CN200710202886 A CN 200710202886A CN 101176708 A CN101176708 A CN 101176708A
Authority
CN
China
Prior art keywords
carmofur
mannitol
sorbitol
sustained
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007102028868A
Other languages
Chinese (zh)
Other versions
CN100586435C (en
Inventor
孙娟
孙中厚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Lanjin Pharmaceuticals Co Ltd
Original Assignee
Jinan Shuaihua Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Shuaihua Pharmaceutical Technology Co Ltd filed Critical Jinan Shuaihua Pharmaceutical Technology Co Ltd
Priority to CN200710202886A priority Critical patent/CN100586435C/en
Publication of CN101176708A publication Critical patent/CN101176708A/en
Application granted granted Critical
Publication of CN100586435C publication Critical patent/CN100586435C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The invention relates to a slow-release implant agent of carmofur, which is characterized in comprising effective amounts of carmofur, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly PLA and PLGA. The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases carmofur on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can be also widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.

Description

A kind of Carmofur sustained-release implantation agent for the treatment of entity tumor
(1) technical field
The present invention relates to a kind of Carmofur sustained-release implantation agent for the treatment of entity tumor, belong to technical field of pharmaceuticals.
(2) background technology
Though the research about cancer has obtained bigger progress, its mortality rate still occupies the prostatitis of the various common causes of the death.In China 1,600,000 people's cancer strickens are arranged approximately every year, nearly 1,300,000 people die from cancer, account for 1/5th of total death toll.Cancer morbidity rises year by year and is rejuvenation trend, has data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, and mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Therefore, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
For many years, carmofur is used as treatment multiple myeloma choice drug always.The effect that is used for the treatment of other tumor separately is unclear.Though unite some tumor tool is had certain effect, limited its clinical practice by the caused whole body toxic and side effects of conventional route administration with other anticarcinogen.
The carmofur local sustained release can obviously improve its general toxicity and to the therapeutic effect of kinds of tumors, see Chinese patent (ZL200510042428.3).Yet existing slow releasing agent is released and is wanted the short and significantly prominent phenomenon of releasing of existence of cycle.
(3) summary of the invention
Based on examination to prior art, the present invention has carried out a large amount of comparisons to existing adjuvant and the slow release regulator that may influence drug release, found that carmofur is in polyester (polyesters) family macromolecule, particularly under the condition of polyester such as PLA and PLGA and the existence of slow release regulator, have more stable release behavior, entity tumors such as cervical cancer, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer and rectal cancer are had comparatively significantly action effect.Discover that further the carmofur local sustained release also has good therapeutical effect to the outer entity tumor of other craniums such as thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
No matter be inside and outside drug release behavior or general toxicity or therapeutic effect, the interpolation of the slow release regulator of given dose all shows beyond thought effect.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of multiple entity tumor.
The present invention treats the sustained-release implant of entity tumor, comprises anticancer effective component and slow-release auxiliary material, and wherein anticancer effective component is carmofur (Carmofur) or ftorafur.
This sustained-release implant is made up of one of following composition, all percentage by weight not:
(1) carmofur 1%-40%
(2) slow-release auxiliary material 45%-98.9%
(3) release regulator 0.1%-15%
Total amount is 100%.
Wherein, carmofur can be its various salt, serves as preferred with its hydrochlorate;
The percentage by weight of carmofur in sustained-release implant is 1%-40%, is preferred with 2%-20%, with 5%-15% for choosing is arranged most.
Slow-release auxiliary material is selected from the copolymer of polylactic acid or lactic acid and glycolic,
Wherein, the molecular weight peak value of polylactic acid is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000, with 5000-10000,10000-25000,25000-35000 or 30000-50000 serves as preferred, with 10000-25000,25000-35000 or 30000-50000 choosing is arranged most;
The molecular weight peak value of poly-lactonaphthol and co-glycolic acid is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000, with 5000-10000,10000-25000,25000-35000 or 30000-50000 serves as preferred, with 10000-25000,25000-35000 or 30000-50000 choosing is arranged most; Wherein, the percentage by weight of poly-lactonaphthol and polyglycolic acid is 90: 10,70-80: 20-30,60-40: 40-60,75: 25,25: 75 or 50: 50, with 90: 10 serve as preferably, with 75: 25 and 50: 50 for choosing is arranged most.
Release regulator is selected from a kind of or its combination in mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin; With mannitol, sorbitol, chitin, sodium salt, chrondroitin serves as preferred, with mannitol, sorbitol for most preferably; The percentage by weight of release regulator in sustained-release implant is 0.1%-15%, is preferred with 0.5%-10%, with 1%-8% for choosing is arranged most.
The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.01-300 milligram/patient, is ideal with 1-100 milligram/patient, with 2-50 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, microsphere, nanosphere, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.
Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of sustained-release implant can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded
Each component and the weight percentage in sustained-release implant thereof are preferred one of following in the sustained-release implant:
(1) sodium chloride of the PLGA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(2) sodium chloride of the PLGA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(3) sodium chloride of the PLGA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(4) sodium chloride of the PLGA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(5) sodium chloride of the PLGA of the carmofur of 20%-35%, 60%-79%, 1%-5%, mannitol or sorbitol are poly-;
(6) sodium chloride of the PLA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(7) sodium chloride of the PLA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(8) sodium chloride of the PLA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(9) sodium chloride of the PLA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(10) carmofur of 20%-35% and and sodium chloride, mannitol or the sorbitol of PLA, the 1%-5% of 60%-79% poly-.
Wherein, the molecular weight peak value of polylactic acid (PLA) is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000;
The molecular weight peak value of the copolymer of polylactic acid and polyglycolic acid (PLGA) is 1000-10000,10000-25000,25000-40000 or 40000-60000;
The percentage by weight of poly-lactonaphthol and polyglycolic acid is 90: 10,70-80: 20-30,60-40: 40-60,75: 25,25: 75 or 50: 50;
Above-mentioned sustained-release implant is granular, microsphere, nanosphere, lamellar, sphere, bulk, needle-like, bar-shaped or apperance.
In the sustained-release implant each component and the weight percentage in sustained-release implant thereof with one of following for most preferably:
(1) 1% carmofur, 95% PLGA, 4% chitin, mannitol or sorbitol;
(2) 5% carmofur, 90% PLGA, 5% sodium chloride, mannitol or chrondroitin;
(3) 10% carmofur, 80% PLGA, 10% chitin, mannitol or sorbitol;
(4) 15% carmofur, 80% PLGA, 5% sodium chloride, mannitol or chrondroitin;
(5) 20% carmofur, 75% PLGA, 5% sodium chloride, mannitol or sorbitol are poly-;
(6) 2% carmofur, 90% PLA, 8% chitin, mannitol or sorbitol;
(7) 7.5% carmofur, 85% PLA, 7.5% sodium chloride, mannitol or chrondroitin;
(8) 10% carmofur, 75% PLA, 5% chitin, mannitol or sorbitol;
(9) 12.5% carmofur, 70% PLA, 12.5% sodium chloride, mannitol or chrondroitin;
(10) 25% carmofur, 70% PLA, 5% sodium chloride, mannitol or sorbitol are poly-.
Wherein, the molecular weight peak value of polylactic acid (PLA) is 10000-25000,25000-35000 or 30000-50000; The molecular weight peak value of the copolymer of lactic acid and glycolic (PLGA) is 10000-25000,25000-40000 or 40000-60000; The percentage by weight of lactonaphthol and glycolic is 75: 25,25: 75 or 50: 50.
Each component and the weight percentage in sustained-release implant thereof also comprise one of following in the most preferred sustained-release implant:
(1) 5% carmofur, 90% PLGA, 5% mannitol or sorbitol;
(2) 10% carmofur, 80% PLGA, 10% mannitol;
(3) 10% carmofur, 80% PLGA, 10% sorbitol;
(4) 15% carmofur, 80% PLGA, 5% sodium chloride or mannitol;
(5) 20% carmofur, 75% PLGA, 5% mannitol;
(6) 5% carmofur, 90% PLA, 5% mannitol or sorbitol;
(7) 7.5% carmofur, 85% PLA, 7.5% mannitol;
(8) 10% carmofur, 75% PLA, 5% chitin, mannitol or sorbitol;
(9) 12.5% carmofur, 70% PLA, 12.5% mannitol or chrondroitin;
(10) 15% carmofur, 75% PLA, 5% mannitol or sorbitol are poly-.
Wherein, the molecular weight peak value of polylactic acid is 15000-30000; The molecular weight peak value of the copolymer of lactic acid and glycolic is 15000-30000; The percentage by weight of lactonaphthol and glycolic is 50: 50.
Sustained-release implant is used for the treatment of entity tumor, comprises the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, osteosarcoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, tumor of head and neck and comes from former or cancer, sarcoma or the carcinosarcoma of secondary of gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
Anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, this sustained-release implant can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer sustained-released implantation agent of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Studies show that carmofur (15ug/ml) is added in 24 hours the various tumor cells of In vitro culture, continue to cultivate after 48 hours the counting cells sum and calculate its suppression ratio (%) growth of tumour cell.The result shows that carmofur has the obvious suppression effect to multiple solid tumor cell growth.To the suppression ratio of growth of tumour cell such as hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, skin carcinoma and carcinoma of testis at 60%-96%.
Further research table carmofur all has obvious inhibitory action (P<0.05) to the growth of the metastatic tumor of osteosarcoma and above-mentioned tumor.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of the entity tumor of metastasis provides new selection.
The preparation method of sustained-release implant of the present invention is as follows:
1, the slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as;
2, adding the slow release regulator of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement;
3, adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement;
4, remove organic solvent.Vacuum drying or cold drying all can.
5, dried solid sustained-release implant is made different shape as required.
6, ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
The the 2nd and 3 goes on foot and can carry out simultaneously or with different orders, depends primarily on stability of drug.
(4) specific embodiment
Embodiment one,
(molecular weight is 15000-25000PLGA with the slow-release auxiliary material of weighing, 50: 50) put into different containers respectively with slow release regulator (mannitol), add the carmofur that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 1% carmofur contains 1mg carmofur, 99mgPLGA
(a) 1% carmofur contains 1mg carmofur, 95mgPLGA, 4mg mannitol;
(B) 5% carmofur, contain 5mg carmofur, 95mgPLGA;
(b) 5% carmofur, contain 5mg carmofur, 91mgPLGA, 4mg mannitol;
(C) 10% carmofur, contain 10mg carmofur, 90mgPLGA;
(c) 10% carmofur, contain 10mg carmofur, 80mgPLGA, 10mg mannitol;
(D) 15% carmofur, contain 15mg carmofur, 85mgPLGA;
(d) 15% carmofur, contain 15mg carmofur, 80mgPLGA, 5mg mannitol;
(E) 20% carmofur, contain 20mg carmofur, 80mgPLGA;
(e) 20% carmofur, contain 20mg carmofur, 75mgPLGA, 5mg mannitol.
Embodiment two
10 sustained-release implants among the embodiment one are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (C), (D) and (E) five Carmofur sustained-release implantation agents that do not contain slow release regulator (mannitol) prominent to release phenomenon obvious, it is prominent releases phenomenon and mostly occurs at 22-30 days, account for the 60-80% of total content of dispersion, and (a), (b), (c), (d) and (e) the prominent phenomenon of releasing of Carmofur sustained-release implantation agent that etc. contains slow release regulator (mannitol) is obviously not obvious, and drug slow discharges 3-5 week.
Embodiment three
(molecular weight is the PLGA of 20000-30000 with the slow-release auxiliary material of weighing, 75: 25) put into different containers respectively with slow release regulator (mannitol), add the carmofur that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 1% carmofur contains 1mg carmofur, 99mgPLGA
(a) 1% carmofur contains 1mg carmofur, 95mgPLGA and 4mg sorbitol;
(B) 5% carmofur, contain 5mg carmofur, 95mgPLGA;
(b) 5% carmofur, contain 5mg carmofur, 91mgPLGA and 4mg sorbitol;
(C) 10% carmofur, contain 10mg carmofur, 90mgPLGA;
(c) 10% carmofur, contain 10mg carmofur, 80mgPLGA and 10% sorbitol;
(D) 15% carmofur, contain 15mg carmofur, 85mgPLGA;
(d) 15% carmofur, contain 15mg carmofur, 80mgPLGA, 5mg sorbitol;
(E) 20% carmofur, contain 20mg carmofur, 80mgPLGA;
(e) 20% carmofur, contain 20mg carmofur, 75mgPLGA, 5mg sorbitol.
Embodiment four
10 sustained-release implants among the embodiment three are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (C), (D) and (E) five Carmofur sustained-release implantation agents that do not contain slow release regulator (sorbitol) prominent to release phenomenon obvious, it is prominent releases phenomenon and mostly occurs at 24-35 days, account for the 40-60% of total content of dispersion, and (a), (b), (c), (d) and (e) the prominent phenomenon of releasing of Carmofur sustained-release implantation agent that etc. contains slow release regulator (mannitol) is obviously not obvious, and drug slow discharges 28-35 days.
Embodiment five
The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-25000) of weighing is put into different containers respectively with slow release regulator (sodium chloride), add the carmofur that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 2% carmofur contains 2mg carmofur, 98mg PLA;
(a) 2% carmofur contains 2mg carmofur, 90mg PLA, 8mg sodium chloride;
(B) 7.5% carmofur, contain 7.5mg carmofur, 92.5mg PLA;
(b) 7.5% carmofur, contain 7.5mg carmofur, 85mg PLA, 7.5mg sodium chloride;
(C) 10% carmofur, contain 10mg carmofur, 90mg PLA;
(c) 10% carmofur, contain 10mg carmofur, 85mg PLA, 5mg sodium chloride;
(D) 12.5% carmofur, contain 12.5mg carmofur, 87.5mg PLA;
(d) 12.5% carmofur, contain 12.5mg carmofur, 75mg PLA, 12.5mg sodium chloride;
(E) 25% carmofur, contain 25mg carmofur, 75mg PLA;
(e) 25% carmofur, contain 25mg carmofur, 70mg PLA, 5mg sodium chloride.
Embodiment six
10 sustained-release implants among the embodiment five are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (C), (D) and (E) five Carmofur sustained-release implantation agents that do not contain slow release regulator (sodium chloride) prominent to release phenomenon obvious, it is prominent releases phenomenon and mostly occurs at 22-28 days, account for the 40-50% of total content of dispersion, and (a), (b), (c), (d) and (e) the prominent phenomenon of releasing of Carmofur sustained-release implantation agent that etc. contains slow release regulator (mannitol) is obviously not obvious, and drug slow discharges 28-34 days.
Embodiment seven
(molecular weight is 25000-40000PLGA with the slow-release auxiliary material of weighing, 75: 25) put into different containers respectively with slow release regulator (mannitol), add the carmofur that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(1) 5% carmofur, 90% PLGA, 5% mannitol or sorbitol;
(2) PLGA of the carmofur of 5%-10%, 80%-93%, 2%-10% mannitol or sorbitol;
(3) PLGA of the carmofur of 10%-15%, 75%-89%, 1%-10% mannitol or sorbitol;
(4) PLGA of the carmofur of 15%-20%, 84%-85%, 1%-5% mannitol or sorbitol;
(5) 20%% carmofur, 75% PLGA, 5% mannitol or sorbitol are poly-.
Embodiment eight
Make sustained-release implant by embodiment one, three, five described methods, contained anticancer effective component that different is is one of following:
(1) sodium chloride of the PLGA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(2) sodium chloride of the PLGA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(3) sodium chloride of the PLGA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(4) sodium chloride of the PLGA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(5) sodium chloride of the PLGA of the carmofur of 20%-35%, 60%-79%, 1%-5%, mannitol or sorbitol are poly-;
(6) sodium chloride of the PLA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(7) sodium chloride of the PLA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(8) sodium chloride of the PLA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(9) sodium chloride of the PLA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(10) carmofur of 20%-35% and and sodium chloride, mannitol or the sorbitol of PLA, the 1%-5% of 60%-79% poly-.
Wherein, the molecular weight peak value of polylactic acid (PLA) is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000;
The molecular weight peak value of the copolymer of polylactic acid and polyglycolic acid (PLGA) is 1000-10000,10000-25000,25000-40000 or 40000-60000;
The percentage by weight of poly-lactonaphthol and polyglycolic acid is 90: 10,70-80: 20-30,60-40: 40-60,75: 25,25: 75 or 50: 50.
Embodiment nine
(molecular weight is 15000-25000PLGA with the slow-release auxiliary material of weighing, 50: 50) put into different containers respectively with slow release regulator (mannitol), add the carmofur that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(1) 5% carmofur, 90% PLGA, 5% mannitol;
(2) 10% carmofur, 83% PLGA, 7% mannitol;
(3) 15% carmofur, 75% PLGA, 10% mannitol;
(4) 20% carmofur, 77.5% PLGA, 2.5% mannitol;
(5) 25%% carmofur, 70% PLGA, 5% mannitol.
The drug release time of above sustained-release implant in external normal saline is 25-35 days, is 25-40 days at the subcutaneous drug release time of mice.All there be not prominent releasing.
Embodiment ten
After the subcutaneous implantation of implant mice among the embodiment one, take out to be placed in the room temperature normal saline with different time and soak, survey the burst size of different time medicine (carmofur), and calculate accumulative total and discharge percent (%).Be shown in Table 1.
Table 1
Embodiment one 1 day 3 days 5 days 7 days 14 days 21 days 28 days 35 days 42 days 56 days
(A) 1.2 2.2 3.4 4.6 12 50 70 82 96 100
(a) 2 8 14 22 40 50 60 72 84 92
(B) 2 4 4.6 7 8 48 72 78 86 98
(b) 2.4 12 18 24 48 54 62 76 88 96
(C) 2.1 3.3 4.2 6 10 62 80 88 96 98
(c) 2.0 7.9 16 23.6 42.8 56 64 78 84 92
(D) 1.2 3.1 5.2 6.8 10 58 78 89 96 100
(d) 3 7.2 18 24 41 52 68 80 90 98
(E) 1.1 3.0 5.0 7.3 8.2 58 76 86 94 98
(e) 2.1 11 18 26.0 39 52 68 82 88 94
Table 1 discharges data and shows, does not contain the Carmofur sustained-release implantation agent (A), (B), (C), (D) of regulator and (E) discharges lessly in two weeks, is no more than 15%, concentrates release above 40% between week at 2-3; And contain the Carmofur sustained-release implantation agent (a) and (b), (c), (d) of regulator and (e) discharging slowly steadily, do not have prominent releases phenomenon in 3-6 week average deenergized period.This unexpected formation another major technique feature of the present invention of finding is for the better control drug release time provides new guidance.
On this basis, the present invention finds that further body is implanted into carmofur other entity tumors such as bone tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are had better therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
Tumor is implanted into the inhibitory action of carmofur implant to entity tumor
Method and step: tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, and (inoculation back the 14th day) is divided into 11 groups at random with animal, 10 every group when diameter of tumor grows to the 0.gcm left and right sides.Be the normal saline group, do not contain regulator carmofur implant group (hereinafter to be referred as the carmofur group), contain the carmofur local injection group (be called for short carmofur regulator) of regulator.With 70% alcohol disinfecting tumor surface skin, select to cut off the long otch of 1mm apart from tumor lower edge 1cm place, with puncture needle with in the implant implantation tumour tissue.Sew up the incision and prevent that implant from spilling.Put to death animal in 20 days with vernier caliper measurement tumor size after the implant embedding in per 3 days, the back of weighing is complete peels off tumor and claims tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 11 tumors are implanted into the tumor-inhibiting action of carmofur spit of fland sustained-release implant to Mice Bearing Lewis Lung Cancer
The Carmofur sustained-release implantation agent that makes with step check embodiment one is to the tumor-inhibiting action of Mice Bearing Lewis Lung Cancer according to the method described above.The carmofur implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Carmofur group (A), (B), (C), (D) and tumor control rate (E) are respectively 23%, 49%, 60%, 70% and 76%; And the Carmofur sustained-release implantation agent (a) and (b), (c), (d) and the tumor control rate (e) that contain regulator are respectively 43%, 59%, 75%, 86% and 90%.The P value is all less than 0.001.Repeated experiments P value is all less than 0.001, and difference has the height statistical significance.The tumour inhibiting rate that contains the Carmofur sustained-release implantation agent of regulator obviously surpasses the Carmofur sustained-release implantation agent group that does not contain regulator, twice experimental result good reproducibility.It should be noted that especially, carmofur group (A), (B), (C), (D) and (E) in, the average weight of animal contain the Carmofur sustained-release implantation agent (a) and (b), (c), (d) of regulator and (e) group obviously alleviate, wherein (C), (D) and (E) in have 20%, 50% and 60% animal dead in advance respectively, and death focused mostly between 20-30 days.Therefore illustrate that prominent the releasing of medicine may be the main cause that causes toxic reaction.And containing the Carmofur sustained-release implantation agent (a) and (b) of regulator, (c), (d) and (e) group, no animal dead.This is unexpected finds to constitute another major technique feature of the present invention, provides another new selection and guidance for what use Carmofur sustained-release implantation agent treatment entity tumor.
Embodiment 12 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to mouse breast cancer
The Carmofur sustained-release implantation agent that makes with step check embodiment three is to the tumor-inhibiting action of mouse breast cancer according to the method described above.The carmofur implant of experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.The Carmofur sustained-release implantation agent (a) and (b), (c), (d) and the tumor control rate (e) that contain regulator are respectively 44%, 58%, 76%, 84% and 86%.The P value is all less than 0.001.Repeated experiments P value is all less than 0.001, and difference has the height statistical significance.
Embodiment 13 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to rat liver cancer
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of rat liver cancer.The carmofur implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 53%, 56%, 68%, 74% and 84%.Compare with matched group, the P value is equal to or less than 0.001.
Embodiment 14 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to the mice esophageal carcinoma
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mice esophageal carcinoma.The carmofur implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 42%, 54%, 68%, 74% and 82%.Compare with matched group, the P value is all less than 0.001.
Embodiment 15 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to mouse pancreas cancer
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse pancreas cancer.The carmofur implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 30%, 40%, 57%, 68% and 76%, compares with matched group, and the P value is all less than 0.001.
Embodiment 16 Carmofur sustained-release implantation agents are to the tumor-inhibiting action of the subcutaneous plantation ovarian cancer of mice
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the mice tumor-inhibiting action of plantation ovarian cancer down.The carmofur implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 50%, 56%, 66%, 74% and 86%.Compare with matched group, the P value is equal to or less than 0.001.
Embodiment 17 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to mouse cervical cancer
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse cervical cancer.The carmofur implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 42%, 52%, 72%, 78% and 80%.Compare with matched group, the P value is all less than 0.001.
Embodiment 18 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to the mice carcinoma of prostate
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mice carcinoma of prostate.The carmofur implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 30%, 44%, 57%, 67% and 78%, compares with matched group, and the P value is all less than 0.001.
Embodiment 19 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to Mouse Gastric Cancer
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of Mouse Gastric Cancer.The carmofur implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 44%, 50%, 76%, 78% and 88%.Compare with matched group, the P value is all less than 0.001.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of Carmofur sustained-release implantation agent to mouse junction cancer
The Carmofur sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse junction cancer.The carmofur implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmofur implant is respectively 30%, 38%, 50%, 58% and 78%, compares with matched group, and the P value is all less than 0.001.
In addition, tumor is implanted into the Carmofur sustained-release implantation agent that contains the slow release regulator other entity tumors such as bladder cancer, carcinoma of testis, colon cancer, carcinoma of endometrium, osteosarcoma, nasopharyngeal carcinoma, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses equivalent not Carmofur sustained-release implantation agent and the carmofur lumbar injection group and the local injection group of slow release regulator.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
The foregoing description is to be used for illustrating and also unrestricted the present invention that concrete performance is based on claim.

Claims (10)

1. Carmofur sustained-release implantation agent for the treatment of entity tumor is characterized in that this sustained-release implant is made up of one of following composition, all percentage by weight not:
(1) carmofur 1%-40%
(2) slow-release auxiliary material 45%-98.9%
(3) release regulator 0%-15%
Total amount is 100%, wherein, slow-release auxiliary material is selected from the copolymer of polylactic acid or lactic acid and glycolic, and release regulator is selected from a kind of or its combination in mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
2. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) sodium chloride of the PLGA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(2) sodium chloride of the PLGA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(3) sodium chloride of the PLGA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(4) sodium chloride of the PLGA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(5) sodium chloride of the PLGA of the carmofur of 20%-35%, 60%-79%, 1%-5%, mannitol or sorbitol are poly-;
(6) sodium chloride of the PLA of the carmofur of 1%-5%, 90%-98%, 1%-5%, mannitol or sorbitol;
(7) sodium chloride of the PLA of the carmofur of 5%-10%, 80%-93%, 2%-10%, mannitol or sorbitol;
(8) sodium chloride of the PLA of the carmofur of 10%-15%, 75%-89%, 1%-10%, mannitol or sorbitol;
(9) sodium chloride of the PLA of the carmofur of 15%-20%, 84%-85%, 1%-5%, mannitol or sorbitol;
(10) carmofur of 20%-35% and and sodium chloride, mannitol or the sorbitol of PLA, the 1%-5% of 60%-79% poly-.
3. according to claim 1 and 2 described sustained-release implants, the molecular weight peak value that it is characterized in that described polylactic acid is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000.
4. according to claim 1 and 2 described sustained-release implants, the molecular weight peak value that it is characterized in that the copolymer of described polylactic acid and polyglycolic acid is 1000-10000,10000-25000,25000-40000 or 40000-60000; The percentage by weight of poly-lactonaphthol and polyglycolic acid is 90: 10,70-80: 20-30,60-40: 40-60,75: 25,25: 75 or 50: 50.
5. claim 1 and 2 described sustained-release implants is characterized in that this sustained-release implant is granular, microsphere, nanosphere, lamellar, sphere, bulk, needle-like, bar-shaped or apperance.
6. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) 1% carmofur, 95% PLGA, 4% chitin, mannitol or sorbitol;
(2) 5% carmofur, 90% PLGA, 5% sodium chloride, mannitol or chrondroitin;
(3) 10% carmofur, 80% PLGA, 10% chitin, mannitol or sorbitol;
(4) 15% carmofur, 80% PLGA, 5% sodium chloride, mannitol or chrondroitin;
(5) 20% carmofur, 75% PLGA, 5% sodium chloride, mannitol or sorbitol are poly-;
(6) 2% carmofur, 90% PLA, 8% chitin, mannitol or sorbitol;
(7) 7.5% carmofur, 85% PLA, 7.5% sodium chloride, mannitol or chrondroitin;
(8) 10% carmofur, 75% PLA, 5% chitin, mannitol or sorbitol;
(9) 12.5% carmofur, 70% PLA, 12.5% sodium chloride, mannitol or chrondroitin;
(10) 25% carmofur, 70% PLA, 5% sodium chloride, mannitol or sorbitol are poly-.
7. the sustained-release implant according to claim 6, the molecular weight peak value that it is characterized in that described polylactic acid is 10000-25000,25000-35000 or 30000-50000; The molecular weight peak value of the copolymer of lactic acid and glycolic is 10000-25000,25000-40000 or 40000-60000; The percentage by weight of lactonaphthol and glycolic is 75: 25,25: 75 or 50: 50.
8. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) 5% carmofur, 90% PLGA, 5% mannitol or sorbitol;
(2) 10% carmofur, 80% PLGA, 10% mannitol;
(3) 10% carmofur, 80% PLGA, 10% sorbitol;
(4) 15% carmofur, 80% PLGA, 5% sodium chloride or mannitol;
(5) 20% carmofur, 75% PLGA, 5% mannitol;
(6) 5% carmofur, 90% PLA, 5% mannitol or sorbitol;
(7) 7.5% carmofur, 85% PLA, 7.5% mannitol;
(8) 10% carmofur, 75% PLA, 5% chitin, mannitol or sorbitol;
(9) 12.5% carmofur, 70% PLA, 12.5% mannitol or chrondroitin;
(10) 15% carmofur, 75% PLA, 5% mannitol or sorbitol are poly-.
9. described according to Claim 8 sustained-release implant, the molecular weight peak value that it is characterized in that described polylactic acid is 15000-30000; The molecular weight peak value of the copolymer of lactic acid and glycolic is 15000-30000; The percentage by weight of lactonaphthol and glycolic is 50: 50.
10. the sustained-release implant according to claim 1, the anticancer effective component that it is characterized in that this sustained-release implant are used to prepare the treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, osteosarcoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, skin carcinoma, tumor of head and neck and come from the medicine of cancer, sarcoma or the carcinosarcoma of peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node former or secondary.
CN200710202886A 2007-12-06 2007-12-06 A kind of carmofur sustained-release implant for treating solid tumors Expired - Fee Related CN100586435C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200710202886A CN100586435C (en) 2007-12-06 2007-12-06 A kind of carmofur sustained-release implant for treating solid tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200710202886A CN100586435C (en) 2007-12-06 2007-12-06 A kind of carmofur sustained-release implant for treating solid tumors

Publications (2)

Publication Number Publication Date
CN101176708A true CN101176708A (en) 2008-05-14
CN100586435C CN100586435C (en) 2010-02-03

Family

ID=39403229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200710202886A Expired - Fee Related CN100586435C (en) 2007-12-06 2007-12-06 A kind of carmofur sustained-release implant for treating solid tumors

Country Status (1)

Country Link
CN (1) CN100586435C (en)

Also Published As

Publication number Publication date
CN100586435C (en) 2010-02-03

Similar Documents

Publication Publication Date Title
CN101185633A (en) Neratinib sustained-release implant for treating solid tumor
CN101176713B (en) Carmustine sustained-release implantation agent for curing entity tumour
CN101219102A (en) Lapatinib sustained-release implantation agent for treating solid tumors
CN101185627B (en) Nilotinib sustained-release implant for treating solid tumor
CN100563644C (en) A kind of carmustine sustained-release implantation agent for the treatment of entity tumor
CN101181230A (en) Estramustine sustained-release implantation agent for curing entity tumour
CN101204365A (en) Implant agent treating for solid tumor
CN101224185A (en) Bosutinib sustained release implant for treating solid tumors
CN101204366A (en) Melphalan sustained-release implant treating for solid tumor
CN101181232B (en) Marseilledinun sustained-release implantation agent for curing entity tumour
CN101185629A (en) Decitabine sustained-release preparation for treating solid tumor
CN101204367A (en) Axitinib sustained-release implplant treating for solid tumor
CN101219101A (en) Fludarabine sustained-release implantation agent for treating solid tumors
CN101176710A (en) Mitoxantrone sustained-release implantation agent for curing entity tumour
CN101176712A (en) Nimustine sustained-release implantation agent for curing entity tumour
CN101176714A (en) Meifaron sustained-release implantation agent for curing entity tumour
CN101181229A (en) Busulfan sustained-release implantation agent for curing entity tumour
CN101181231B (en) Sustained-release implantation agent of urotrotiken
CN101204369A (en) Sorafenib sustained-release implant treating for solid tumor
CN101181235B (en) Tantudinun sustained-release implantation agent for curing entity tumour
CN101176709A (en) Beisalutin sustained-release implantation agent for curing entity tumour
CN101229119A (en) Sustained release ocular implant for treating solid tumors
CN101181234B (en) Literdinun sustained-release implantation agent for curing entity tumour
CN101185625B (en) Rubitecan sustained-release implant for treating solid tumor
CN101219105A (en) Emtricitabine sustained-release implantation agent for treating solid tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan

Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

ASS Succession or assignment of patent right

Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD.

Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD.

Effective date: 20120815

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120815

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100203

Termination date: 20161206

CF01 Termination of patent right due to non-payment of annual fee